The VEGFR2-inhibiting tyrosine-kinase inhibitor sunitinib and the anti-VEGFA antibody bevacizumab have been shown to reverse tumor endothelial cell anergy and stimulate lymphocyte infiltration in human renal cell cancer treated with these drugs in a neoadjuvant fashion [8]. This evidence concerns the gene KDR and neoplasm.